ClinConnect ClinConnect Logo
Search / Trial NCT07097805

Glycemic Improvement With Team, Technology, Education and Peer Resources in Type 1 Diabetes-GLITTER Study

Launched by SECOND XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY · Jul 24, 2025

Trial Information

Current as of August 27, 2025

Recruiting

Keywords

Type 1 Diabetes Comprehensive Management

ClinConnect Summary

The GLITTER study is looking at a new way to help people with type 1 diabetes better manage their condition. It combines support from a healthcare team, the use of technology, education about diabetes, and connections with peers who have similar experiences. The goal is to improve how well participants control their blood sugar levels through this all-around approach.

Anyone with type 1 diabetes can join, no matter their age or how long they’ve had the condition. To be eligible, participants must have been diagnosed by a specialist and meet certain medical criteria, like starting insulin treatment after diagnosis or having specific blood tests related to the disease. Those who take part can expect to work closely with healthcare professionals, use helpful technology, learn more about managing diabetes, and connect with others for support. This study is currently recruiting participants and aims to make living with type 1 diabetes a little easier and healthier.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Patients with type 1 diabetes of all age groups, regardless of disease duration.
  • The diagnosis criteria for type 1 diabetes are met by fulfilling any one point from the first two criteria plus any one point from the third criterion.
  • 1. Clinically diagnosed as Type 1 Diabetes by a specialist physician.
  • 2. Meet any one of the following criteria:
  • A. Age of onset \<15 years B. No obesity at the time of onset C. diabetic ketoacidosis onset D. Maximum random C-peptide \<200 pmol/L
  • 3. Meet any one of the following criteria:
  • A. Initiation and continuation of insulin therapy after diagnosis (excluding pancreas or islet transplantation) B. Positive for islet cell antibodies

About Second Xiangya Hospital Of Central South University

The Second Xiangya Hospital of Central South University is a leading academic medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its state-of-the-art facilities and a multidisciplinary team of experts to conduct rigorous investigations aimed at improving patient outcomes. With a strong emphasis on translational medicine, the hospital collaborates with various stakeholders to explore novel therapeutic strategies across a range of medical specialties, contributing significantly to the global clinical research landscape.

Locations

Beijing, Beijing, China

Beijing, Beijing, China

Guangzhou, Guangdong, China

Shenzhen, Guangdong, China

Luoyang, Henan, China

Changsha, Hunan, China

Nanjing, Jiangsu, China

Shenyang, Liaoning, China

Chengdu, Sichuan, China

Hangzhou, Zhejiang, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported